

MCKESSON CORP
Form DEFA14A
June 26, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

McKesson Corporation
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transaction applies:

Edgar Filing: MCKESSON CORP - Form DEFA14A

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

.. Fee paid previously with preliminary materials.

.. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

2014 Annual Meeting of Stockholders
Meeting Date: July 30, 2014

2

2

Executive Summary

We ask for your support at our 2014 Annual Meeting

Delivered Strong

Performance

Superior financial and operational performance in FY 2014

Revenues of \$137.6B (13% increase from FY 2013)

Operating cash flow of \$3.1B (24% increase from FY 2013)

Adjusted EPS of \$8.35 (31% increase from FY 2013)

65%

total
shareholder

return

for

the

fiscal

year

ended

March

31,

2014

Successfully executed on strategic and operational initiatives, including the \$8B international acquisition of Celesio AG

Robust Governance

Structure is Informed

by Shareholder

Feedback

We value shareholder feedback in the refinement of our compensation and governance practices

We implemented and expanded our Lead Independent Director role

We have committed to submit a proxy access by-law amendment to our shareholders in 2015

Continued

Improvements to the

Compensation Program

After our 2013 Annual Meeting, we engaged with over 50% of our shareholder base to understand their concerns

We made meaningful changes to our CEO's pension benefit, our executive pay magnitude and incentive plan design

Independent and

Experienced Board

8 of 9 director nominees are independent

Our directors bring a balance of industry-specific and functional expertise

We

are

refreshing

our

Board

we

added

1

new

director

in

April

2014

and
expect
4 of our existing directors to retire over the next 3 years (including 1 at the 2014
Annual Meeting)

3
3
A History of Strong, Sustained Performance
Key Operational,
Financial and
Strategic
Achievements
Delivered significant, profitable growth on a top-line, bottom-line, and cash flow basis
Undertook strategic and operational actions focusing on areas where we have a leading
position in order to improve our efficiency and enhance our ability to continually innovate

for our customers

Continued execution of disciplined strategic transactions, most recently the \$8B acquisition of Celesio AG that expands McKesson's global platform

Balanced capital allocation policy with significant capital return to shareholders through both stock repurchases and dividends

Our Executive Team and experienced Board

have driven tremendous long-term value for our shareholders

1-Year TSR

3-Year TSR

TSR Since Mr.

Hammergren

Named CEO in

FY 2002

127%

88%

29%

195%

80%

25%

628%

129%

65%

0%

100%

200%

300%

400%

500%

600%

700%

McKesson

FY 2014 Compensation Peer Group

(Market Cap Weighted Average)

S&P 500 Health Care Index

Responsive to 2013 Vote and
Subsequent Shareholder Feedback

4

Ongoing Board
Committee

Refreshment

Clawback Policy

Enhanced Based

On Shareholder

Proposal

Compensation Committee implemented changes to address concerns regarding the scale

of the CEO's pension and the quantum of his pay

o

Reduced pension by \$45M and set a fixed value for pension benefit

o

Eliminated volatility in pension due to changes in actuarial assumptions

Alton Irby, former Chair of the Compensation Committee, has stepped off that Committee

Jane

Shaw

joined

the

Compensation

Committee

and

assumed

the

role

of

Committee

Chair

New Director N. Anthony Coles joined the Compensation Committee in April 2014

Wayne Budd was appointed Chair of the Governance Committee

Policy previously required intentional misconduct or a material negative revision of financial or operating measures to trigger a clawback

o

Intent

and Materiality

restrictions were eliminated, providing the Compensation

Committee greater flexibility in determining when to trigger a clawback

Policy now requires public disclosure of the results of any deliberations regarding whether to recoup compensation, except where prevented by legal or privacy concerns

We

engaged

with

over

50%

of

our

shareholders

to

understand

areas

of

concern

and made meaningful changes in response to shareholder feedback

Substantive

Compensation

Program Changes

Made to CEO Pay

What's New: Executive Compensation
Evaluation of Our CEO's Pension Benefit

5

Some shareholders had concerns regarding the scale of our CEO's pension benefit

The CEO's pension benefit is provided under a legacy pension benefit plan and an employment agreement from 1999

The annual increase in pension accumulation is reflected in the Summary Compensation Table and can cause spikes in total disclosed compensation

Change reported in 2013 resulted from

adjustments to actuarial / interest rate assumptions, which were required in light of a long period of historically low interest rates

Representatives of the Board and management reached out to shareholders to understand their perspectives following the 2013 say on pay vote

The Compensation Committee evaluated possible changes to the CEO's pension in the context of important goals

Drive the right business outcomes for McKesson

Be in the best interests of all shareholders, and responsive to their concerns

Retain and motivate our CEO

6
What's New: Executive Compensation
Changes to the CEO's Pension
Eliminated growth in CEO's pension cost
Eliminated volatility in CEO's pension benefit due to changes in actuarial assumptions
Eliminated CEO's incentive to leave based on a changing interest rate environment
Due to this change, there will be no future change to the value of the pension, which will
simplify Summary Compensation Table disclosure
Fixed the CEO's pension benefit with \$45M reduction (~30%) from the termination benefit
disclosed in 2013

7

What's New: Executive Compensation

FY 2014 Current NEO Compensation Decisions

Base

Salaries

Maintained

CEO base salary since May 2010 and other Current NEO

base salaries since May 2011

Performance

RSUs

Reduced

target
awards
by
an
average
of
6%
from
FY
2013
Option
Awards
Reduced
grant date values by an average of 24% from FY 2013
Long-Term
Incentive
Plan
Reduced
maximum payout opportunity for executive officers by 33%
for
FY
2012

FY
2014
performance
period
Reduced
target
awards
by
an
average
3%
from
FY
2013

FY
2015
performance period
We
heard
our
shareholders
views
about
the
level
of

total
compensation
and responded by reducing nearly every element of our FY 2014 pay program

FY 2010

FY 2014 CEO Direct Pay Down 26%

With Total Shareholder Return of 427%

8

(1)

(2)

Total shareholder return assumes \$100 invested at the close of trading on March 31, 2009 and the reinvestment of dividends w

Total direct compensation (TDC) refers to total compensation disclosed in the Summary Compensation Table minus the am

the Change in Pension Value and Nonqualified Deferred Compensation Earnings column. We exclude this amount because

Compensation Committee decisions based on Company or individual performance.

Executive Compensation
Financial Targets Tied to Operating and Strategic Plans
9
Key Considerations in Development of Financial Targets
for Annual and Long-Term Incentive Plans
Business Environment
Competitive Factors
McKesson Objectives
Public Policy
Analyst Expectations
Market Outlook
Tax Policy
Industry Trends
Competitor Performance
Competitor Plans
Competitive Landscape
Market Growth
Historical Trends
Historical Performance
Long Range Planning

Capital Deployment Opportunities

Recent Capital Deployment Decisions

Long Range Corporate Strategy

Financial

targets

for

annual

and

long-term

incentive

plans

tied

to

1-

year

operating

plan

and

rolling

3-

year strategic plan

This approach has been effective

o

From FY

2012 to FY

2014, McKesson's forward earnings guidance grew by more than 30%,
representing a compound annual growth rate of approximately 15%

o

For FY

2015, forward earnings guidance published on May 12, 2014 was 27% greater than the
actual

earnings

result

for

FY

2014

What's New: Executive Compensation

Incentive Plan Changes for FY 2015

10

Shareholder Concerns

Impact on FY 2015 Incentive Plan

Redundant use of
earnings metrics

Replaced Adjusted EBITDA with Adjusted OCF as secondary
financial metric in Management Incentive Plan (annual cash
incentive)

Replaced Cumulative Adjusted OCF with Adjusted ROIC as
secondary metric in Long-Term Incentive Plan (long-term cash

incentive)
Lack of shareholder return
or relative measure
and
Short performance period
(1-
year) in PeRSU program
Replaced
Performance
Restricted
Stock
Unit
(PeRSU,
former long-
term equity incentive) program with new Total Shareholder
Return
Unit
(TSRU,
new
long-term
equity
incentive)
program
for
executive officers
Adopted TSR relative to S&P 500 Health Care Index as sole
performance metric in new TSR program
o
Target
payout
at
55
th
percentile
relative
to
index
(above
median performance)
o
Payout capped at target if McKesson TSR is negative
All long-term incentive plans for executive officers, including new
TSRU
program,
now
have
performance
or
vesting
periods

of
at
least
3
years

11

Governance Attributes

Our Board actively seeks input from shareholders and is committed to continuously monitoring and maintaining effective governance practices

*

Reflects governance changes adopted or enhanced in last year

Key

Governance

Attributes

Shareholder Right

to Call Special

Meeting *
No Supermajority
Vote Provisions
Majority Voting for
Uncontested Director
Elections
Annual Election
of Directors
8 of 9 Director
Nominees are
Independent
Robust Lead
Independent
Director *
Significant
Director Equity
Ownership
Annual CEO
Succession Review
Regular Executive
Sessions of the Board
No Poison Pill
Related Party
Transactions Policy

12

Independent, Experienced Board with
Diverse Skills & Perspectives

McKesson's Board, with its diverse perspectives, provides valuable guidance,
consultation and oversight for management

Nominees Bring a Balance of Industry-Specific and Functional Expertise

All 9 have served on other public company
boards

2 former leaders of pharmaceutical or medical
device companies

4 nominees with healthcare experience

3 with financial expertise
3 technology industry experts
2 former CFOs
8
Independent
Directors
7
Current or
Former CEOs
2
Females
2
African
Americans
2
Physicians
89%
78%
22%
22%
22%

What's New: Corporate Governance

Ongoing Board Refreshment

13

The Governance Committee continues to identify candidates to join the Board and provide fresh perspectives as new independent Directors

Expected Composition at 2017 AGM**

Current Board Tenure*

N. Anthony Coles, M.D.,

appointed to the Board in

April 2014

o

Former CEO and
Chairman of Onyx
Pharmaceuticals
(NASDAQ:ONXX)

o

Extensive experience in
biopharmaceuticals and
pharmaceuticals

o

Independent under SEC,
New York Stock
Exchange and McKesson
criteria

*Includes

Dr.
Shaw
who
will
be
leaving
the
Board

at
the
upcoming
Annual
Meeting

**Assumes no expansion in Board size

16+ Years

2

1

4

4

1

0-5 Years

6-10 Years

11-15 Years

16+ Years

4

1

2

0-5 Years

6-10 Years

11-15 Years

What's New: Corporate Governance

Expansion of Lead Director Role

14

Preside at all meetings of the Board at which the Chairman is not present, including executive sessions of the independent directors

Serve as liaison between the Chairman and the independent directors

Approve information sent to the

Board

Approve Board meeting agendas and assure that there is sufficient time for discussion of all items

Call meetings of the independent directors, as appropriate

If requested by major shareholders, ensure that he or she is available for direct communication

Lead the annual evaluation of directors and the CEO

Assume role of Chairman of the Board on an interim basis in the event of a temporary or permanent absence of the Chairman

Provide recommendations to the Governance Committee regarding Board committee memberships selection of committee chairs

Retain independent legal, accounting and other advisors

Assist in assuring compliance with, and implementation of, the Corporate Governance Guidelines

Core Roles and Responsibilities of Lead Independent Director

Expansion of Lead Independent Director's Powers

Created role in

January 2013,

effective July 2013

Expanded role in

October 2013

What's New: Governance

Proxy Access By-Law in 2015

15

We recently announced plan to submit a proposal at the 2015 Annual Meeting to adopt a proxy access by-law amendment. Discussed proxy access with shareholders in reaching decision 3% ownership with a 3-year holding period. Shareholders may nominate directors for up to 20% of the available seats.

McKesson's

plan

to

seek
shareholder
approval
of
proxy
access
demonstrates
our
commitment to best practices in corporate governance

Board Perspectives on Shareholder Proposals

Action by Written Consent of Shareholders

16

The Board believes that implementation of this proposal is unnecessary given the ability of shareholders to call special meetings

o

Currently, any matter that either McKesson or its shareholders wish to present for a vote must be presented at an annual or special meeting; this allows all shareholders to consider, discuss and vote on pending shareholder actions

Written consent would permit a small group of shareholders (including those who accumulate a short-term voting position through the borrowing of shares) to initiate action with no prior notice either to the other

shareholders or to the Company

o
Such shareholders may not act in the interests of longer-term holders of our common stock

o
Action by written consent is not subject to notice periods that are vital to informed decision making

o
This could prevent all shareholders from having an opportunity to deliberate in an open and transparent manner, and to consider arguments for and against any action

o
Further, the Board does not have the opportunity to analyze and provide a recommendation, and proponents need

not
provide
any
information
regarding
themselves

or
their
interests

in
the
proposed

action to other shareholders or the Company

A proposal on this topic in 2013 was opposed by 55% of votes cast, while the special meeting right proposed by the Company was overwhelmingly approved, reflecting shareholder preferences

Given the potential for abuse and disenfranchisement of minority shareholders and other

adverse consequences associated with the right to act by less than unanimous written consent, the Board recommends a vote AGAINST

this proposal

Board Perspectives on Shareholder Proposals

Disclosure of Political Contributions

17

McKesson understands that the decisions made by policymakers have a profound impact on our industry, business and customers

McKesson primarily engages in the political process through the McKesson Corporation Employees Political Fund (PAC)

o

Contributions

are

funded
entirely
by
eligible
McKesson
employees
on
a
voluntary
basis;
such
contributions are not made with corporate assets

The
Company
does
not
make
independent
expenditures
or
super
PAC
contributions

The Company does make a limited number of corporate political contributions at the state level

o
This includes corporate contributions to state candidates and political action committees in areas where the Company has a significant employee or facility presence

o
Political contributions are subject to Board oversight, and all contributions must be approved by the Senior Vice President of Public Affairs, with contributions greater than \$1,000 subject to approval by the Chairman of the Board and Chief Executive Officer

We agree that transparency and accountability with respect to political expenditures are important

o
All corporate political contributions are subject to both internal procedures and strict laws regarding transparency

We support transparency in reporting; a link to a database of PAC contributions is made available on our website

at
www.mckesson.com

under
the
caption

About
McKesson-Public
Affairs,

as
well
as
the
aggregate

amount of political contributions and a statement about the Company's political contribution policies. Given the limited nature of McKesson's corporate political contributions, together with recently enhanced transparency and Board oversight of our political engagement, the Board believes this proposal is unnecessary and recommends a vote AGAINST.

Board Perspectives on Shareholder Proposals

Accelerated Vesting of Equity Awards

18

The Board opposes this proposal because providing for accelerated vesting of equity awards in the event of a named executive officer's termination following a change in control is in the best interests of shareholders

o

This

double

trigger

for

accelerated

vesting
is
consistent
with
feedback
from
our
shareholders

o
Executives have employee benefits, including severance and change in control benefits, that the Compensation Committee believes are competitively necessary

o
Adopting this proposal would limit our ability to provide competitive compensation programs and could disadvantage our ability to attract and retain highly qualified employees

Accelerated
vesting

can
help
to
mitigate
some
of
the
uncertainty
that
will
likely
arise
for
executives
from

a
change in control transaction, and reduce the risk of executive turnover during a pending transaction where the risk of job loss is relatively high for senior executives

The Board believes that the current structure of the Company's executive compensation program, including the provisions related to accelerated vesting of equity incentive awards, are appropriate and effective, and align the interests of our executives with those of the Company's shareholders

o
These compensation programs are consistent with market practice and provide us with the ability to compete for, attract and retain talented executives

The Board believes that the current executive compensation structure, including accelerated vesting of equity incentive awards, is appropriate and effective

at aligning the interests of
executives and shareholders

a vote AGAINST
is recommended

19

2014 Annual Meeting of Stockholders

This information is being provided to shareholders in addition to the proxy statement filed by McKesson Corporation (the Company) with the Securities and Exchange Commission (the SEC) on June 19, 2014. Please read the complete proxy statement and accompanying materials carefully before you make a voting decision. Even if voting instructions for your proxy have already been given, you can change your vote at any time before the annual meeting by giving new voting instructions as described in more detail in the proxy statement.

The proxy
statement,
and
any
other
documents
filed
by
the
Company

with
the
SEC,
may
be
obtained free of charge at www.sec.gov
and from the Company's website at
www.mckesson.com.